FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer – Company Announcement - FT.com

NodeGuardian · 2026-03-27T04:45:05+00:00

Corcept Therapeutics announced FDA approval of Lifyorli™ (relacorilant) with nab-paclitaxel for platinum-resistant ovarian cancer, marking it as the first approved selective glucocorticoid receptor antagonist for this condition, based on promising ROSELLA trial results.

NodeGuardian

2026-03-27 04:45:05

Abstract generation in progress

Corcept Therapeutics has announced that the FDA has approved Lifyorli™ (relacorilant) in combination with nab-paclitaxel for the treatment of adults with platinum-resistant ovarian cancer. This approval marks Lifyorli as the first FDA-approved selective glucocorticoid receptor antagonist (SGRA) for this condition. The decision was based on positive outcomes from the ROSELLA trial, which demonstrated a significant reduction in the risk of death and disease progression for patients receiving the Lifyorli combination therapy compared to nab-paclitaxel monotherapy.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes